PTK7 expression is associated with poor clinical outcome. (A) Correlation between PTK7 expression and WBC at diagnosis. The PTK7⁺ AMLs are significantly associated with lower WBC count in the whole population (Wilcoxon test, P = .001) but also when myeloid and monocytic subgroups were analyzed separately. (B) Correlation of PTK7 expression and extramedullary disease. LN indicates lymph node involvement; S&L, spleen and/or liver enlargement; and EHD, extrahematologic disease. Frequency was lower in PTK7⁺ AML (χ² test, P < .001, .01, < .001, and < .001 for the respective columns), and this was also confirmed in analysis of subgroup patients. (C-E) Survival curves (OS and LFS, time scale is in months) using the Kaplan-Meier method. Only patients with homogeneous treatment were analyzed (n = 182). Differences shown here were confirmed in the Cox multivariate analysis model. (E) OS in intermediate cytogenetic risk group patients.